Antonio Clavenna

Dr. Antonio Clavenna

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2017 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Closed access
PDF file
CBChristian J Bachmann
Christian J Bachmann
LAL. Aagaard
L. Aagaard
MBMiquel Bernardo
Miquel Bernardo
LBL. Brandt
L. Brandt
MCM. Cartabia
M. Cartabia
DTD. Taylor
D. Taylor

15 June 2009 in Archives of Disease in Childhood
Verified
Journal Article
Closed access
PDF file
ACAntonio Clavenna
Antonio Clavenna
MBMaurizio Bonati
Maurizio Bonati
Objective: To assess the incidence of adverse drug reactions (ADRs) in the paediatric population and the safety alerts concerning children and adolescents issued by international drug regulatory agencies since 2001. Methods: A bibliographic search was performed in the Medline and Embase databases for prospective studies published between January 2001 and December 2007 evaluating the ADR incidence in the paediatric population. Data were analysed by a random effect model. Moreover, the websites of nine international drug regulatory agencies were searched to collect information on safety alerts concerning the paediatric population. Results: A total of eight prospective studies were evaluated, six of which concerned the ADR incidence in hospitalised children. The overall incidence of ADRs was 10.9% (95% CI 4.8 to 17.0) in hospitalised children and 1.0% (95% CI 0.3 to 1.7) in outpatient children. The rate of hospital admission due to ADRs was 1.8% (95% CI 0.4 to 3.2). The skin and gastrointestinal system were the organs most commonly affected and antibiotics were the drugs most commonly associated with ADRs. Safety alerts in the paediatric population were retrieved for 28 drugs, five of which were for psychotropic drugs and most of which were issued by the Food and Drug Administration (20 drugs). For 12 drugs, warnings were published in the 2006–2007 period. Antidepressants were the only drugs for which alerts were issued by all the drug regulatory agencies. Conclusions: To ensure safe and effective medicines for children, efforts are needed at different levels (governments, drug regulatory agencies, pharmaceutical industries, health care professionals, and parents). Collaborative regulatory initiatives, such as the use of common warnings, can also contribute to a more rational use of drugs for children.

1 November 2002 in Reproductive Toxicology
Verified
Journal Article
Closed access
RERicci, Elena
Ricci, Elena
Fabio ParazziniFabio Parazzini
Fabio Parazzini
TMTiziano Motta
Tiziano Motta
CFCarlo I Ferrari
Carlo I Ferrari
ACAnnamaria Colao
Annamaria Colao
MBMaurizio Bonati
Maurizio Bonati

12 January 2011 in Archives of Disease in Childhood
Verified
Journal Article
Closed access
PDF file
ACAntonio Clavenna
Antonio Clavenna
MBMaurizio Bonati
Maurizio Bonati
Antibiotics represent the most widely prescribed therapeutic agents. The prevalence of drug prescription differs across age, with preschool children being most exposed to antibiotic drugs, especially in the community setting. A review with the aim to compare the profile of antibiotic drug prescription at the multinational, national and regional levels was performed. This overview of drug-utilisation studies found quantitative and qualitative differences in the antibiotic prescription profile between and within countries. Moreover, differences exist also at the local level and between prescribers. In general, second-choice antibiotic drugs (eg, cephalosporins) were more commonly prescribed in settings characterised by a high prevalence of antibiotic prescription. Geographical differences should be taken into account when monitoring antimicrobial drug resistance and when planning educational interventions for health professionals and parents with the aim to improve the rational use of antibiotic drugs.

16 June 2009 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
ACAntonio Clavenna
Antonio Clavenna
MBMaurizio Bonati
Maurizio Bonati

21 September 2007 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
ARAlessandra Rossignoli
Alessandra Rossignoli
ACAntonio Clavenna
Antonio Clavenna
MBMaurizio Bonati
Maurizio Bonati